A new study proposes that two genetic risk factors for frontotemporal dementia interact, disrupting brain connectivity decades before symptoms.
The protein that causes progeria, the accelerated aging disease, hastens pathology in neurons derived from people with Parkinson's.
Merck’s BACE inhibitor has survived its most recent safety evaluation and will undergo more testing in two trials—one for mild to moderate Alzheimer's, the other for mild cognitive impairment due to AD.
First-generation γ-secretase modulators are less potent in human neurons than in some other cell types, possibly explaining why these drugs failed in clinical trials.
A small panel of fluid biomarkers could predict a slow or fast disease course in amyotrophic lateral sclerosis.
Exome sequencing identifies a new Alzheimer’s risk gene—phospholipase D3.
Researchers at a meeting on BACE shared concerns that blocking the protease in adults might have unexpected consequences.
G8 leaders set 2025 as their goal to find better treatment for Alzheimer's and vowed to coordinate research and care strategies.
European Project Mixes Adaptive Design with Trial-Ready Cohort G8 Vows to Improve Care, Cure Dementia G8 Dementia Summit ...
A European public-private partnership plans to combine faster enrollment with adaptive trials to hasten drug discovery in Alzheimer's.
As new substrates and functions for BACE continue to emerge, scientists worry about adverse effects of blocking the protease.
Cloistered Retreat Takes the Pulse of BACE Research BACE—Substrates, Functions, Developmental Phenotypes Blocking BACE—Do Adult Mouse Phenotypes Predict Side Effects? Meeting Explores Complex Biology of BACE Regulation BACE Proteases in Health and Disease ...
Once branded as a difficult target, β-secretase has become the crowd favorite. But might pharma have to cool its jets?
Thought to be no place for translation, RNA granules that form in “FUSopathies” turn out to host protein synthesis, after all.
Sleeping in an MRI scanner, babies with ApoE4 genotype reveal myelination and structural differences in brain areas affected in people with Alzheimer’s disease.